Related Experiment Video
Updated: Apr 15, 2026
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.9K
Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis
Rupert W Major1, Chee Kay Cheung2, Laura J Gray3
1The John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom; and Departments of Health Sciences, and rm157@le.ac.uk.
Summary
Statins effectively lower cardiovascular disease risk in patients with chronic kidney disease (CKD) for primary prevention. This meta-analysis confirms their benefit, aligning with current clinical guidelines for CKD management.
Area of Science:
- Nephrology and Cardiovascular Medicine
- Pharmacological Interventions
- Evidence Synthesis and Meta-Analysis
Background:
- Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with chronic kidney disease (CKD).
- Lipid-lowering therapies, particularly statins, are established for CVD primary prevention in the general population.
- Previous meta-analyses have not specifically focused on primary CVD prevention in CKD patients.
Purpose of the Study:
- To assess the efficacy of lipid-lowering therapies for cardiovascular primary prevention in individuals with chronic kidney disease.
- To synthesize evidence from randomized controlled trials (RCTs) evaluating statins in non-end-stage CKD populations.
Main Methods:
- Systematic review and random-effects meta-analysis.
- Searched MEDLINE and other sources for RCTs published between January 2012 and September 2013.
- Included trials focused on primary prevention with lipid-lowering therapy in non-end-stage CKD.
Main Results:
- Six trials were analyzed, primarily involving patients with stage 3 CKD (5 trials).
- Statins significantly reduced the risk of cardiovascular disease by 41% in CKD stages 1-3 (RR, 0.59; 95% CI, 0.48-0.72).
- Secondary outcomes showed reductions in total mortality (RR, 0.66) and coronary heart disease events (RR, 0.55), with non-significant reduction in stroke.
Conclusions:
- Lipid-lowering therapy with statins is effective for the primary prevention of cardiovascular disease in patients with CKD.
- Findings support current clinical guidelines recommending statin use in all CKD patients for CVD risk reduction.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
01:28Chronic Kidney Disease III: Interprofessional Care
651
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
651
01:25Chronic Kidney Disease I: Introduction
1.2K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
01:26Atherosclerosis III: Management
605
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
01:24Chronic Kidney Disease II: Clinical Manifestations
1.1K
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
01:18Chronic Kidney Disease IV: Nursing Management
667
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
667